CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 1.67: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.59BCNY383.86M · vs all stocks (USD)
Revenue (TTM)
527.86MCNY78.28M · vs all stocks (USD)
Profit Margin
-57.48%Beta
0.1750xvs all stocks
52-Week Change
-2.35%vs all stocks
Market Capitalization
2.59BCNY383.86M · vs all stocks (USD)
Enterprise Value
2.84BCNY421.77M · vs all stocks (USD)
Price to Sales (TTM)
4.90xPrice to Book (MRQ)
3.60xEnterprise to Revenue
5.39xEnterprise to EBITDA
-56.08xGross Margin
42.61%Profit Margin
-57.48%Operating Margin
5.73%Return on Assets (TTM)
-3.42%Return on Equity (TTM)
-37.55%Revenue (TTM)
527.86MCNY78.28M · vs all stocks (USD)
Revenue per Share (TTM)
0.8410CNYUpdated Aug 18, 2026Quarterly Revenue Growth
-13.90%Gross Profit (TTM)
238.69MCNY35.40M · vs all stocks (USD)
EBITDA (TTM)
-50.71MCNY-7.52M · vs all stocks (USD)
Net Income (TTM)
-303.41MCNY-45.00M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-45.61%Operating Cash Flow (TTM)
75.09MCNY11.14M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
36.49MCNY5.41M · vs all stocks (USD)
5-Year Average Dividend Yield
0.22%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
-8.86MCNYFY2025 · Dec 31, 2025Revenue
545.50MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
285.78MCNYFY2025 · Dec 31, 2025Gross Profit
259.71MCNYFY2025 · Dec 31, 2025Operating Income
-93.21MCNY-13.82M · vs all stocks (USD)
Pre-tax Income
-337.03MCNYFY2025 · Dec 31, 2025Income Tax Expense
9.05MCNYFY2025 · Dec 31, 2025Net Income
-346.08MCNYFY2025 · Dec 31, 2025EBIT
-326.04MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-79.92MCNYFY2025 · Dec 31, 2025Research & Development
23.44MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
234.56MCNYFY2025 · Dec 31, 2025Other Operating Expenses
12.27MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.70MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
10.99MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.5100CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.5100CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
628.27MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
628.27MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-346.08MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
25.66MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-84.88MCNYFY2025 · Dec 31, 2025Free Cash Flow
-147.14MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
96.69MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-346.08MCNYFY2025 · Dec 31, 2025Other Non-cash Items
21.14MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
203.79MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
36.28MCNYFY2025 · Dec 31, 2025Capital Expenditures
-62.26MCNYFY2025 · Dec 31, 2025Net Acquisitions
920.67KCNYFY2025 · Dec 31, 2025Sale of Investments
201.97MCNYFY2025 · Dec 31, 2025Other Investing Activity
14.24MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
154.88MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
190.45MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-430.97MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-13.30MCNYFY2025 · Dec 31, 2025Other Financing Charges
-7.99MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-261.81MCNYFY2025 · Dec 31, 2025Shares Outstanding
623.72MSharesUpdated Aug 18, 2026Float Shares
510.81MSharesUpdated Aug 18, 2026% Held by Insiders
25.17%vs all stocks
% Held by Institutions
0.96%vs all stocks
Total Cash (MRQ)
112.37MCNY16.66M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.1800CNYUpdated Aug 18, 2026Total Debt (MRQ)
378.86MCNY56.18M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.5356xCurrent Ratio (MRQ)
0.7960xBook Value per Share (MRQ)
1.15CNYUpdated Aug 18, 2026Total Assets
1.39BCNY206.01M · vs all stocks (USD)
Total Current Assets
459.62MCNYFY2025 · Dec 31, 2025Total Liabilities
682.29MCNYFY2025 · Dec 31, 2025Total Non-current Assets
929.54MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
89.84MCNYFY2025 · Dec 31, 2025Total Current Liabilities
592.46MCNYFY2025 · Dec 31, 2025Cash
101.01MCNYFY2025 · Dec 31, 2025Cash Equivalents
22.27MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
123.28MCNYFY2025 · Dec 31, 2025Accounts Receivable
229.82MCNYFY2025 · Dec 31, 2025Inventory
55.76MCNYFY2025 · Dec 31, 2025Accounts Payable
145.22MCNYFY2025 · Dec 31, 2025Short-term Debt
312.44MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.27MCNYFY2025 · Dec 31, 2025Long-term Debt
50.85MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
4.79MCNYFY2025 · Dec 31, 2025Common Stock (Book)
623.72MCNYFY2025 · Dec 31, 2025Retained Earnings
-105.73MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
706.87MCNY104.83M · vs all stocks (USD)
52-Week Low
3.40CNYUpdated Aug 18, 202652-Week High
4.79CNYUpdated Aug 18, 202652-Week Change
-2.35%vs all stocks
Beta
0.1750xvs all stocks
50-Day MA
3.75CNYUpdated Aug 18, 2026200-Day MA
4.02CNYUpdated Aug 18, 2026Avg 10-Day Volume
18.10MSharesUpdated Aug 18, 2026Avg 30-Day Volume
17.03MSharesUpdated Aug 18, 2026Diluted EPS (TTM)
-0.4800CNYUpdated Aug 18, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.43Profit Margin: -0.57
Financial Health
Altman Z-Score 1.67: grey zoneSignificant
Altman Z-Score: 1.67
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Larimar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Upstream Bio, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hangzhou Tianmu-Shan Pharmaceutical Enterprise Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jilin Province Xidian Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Compass Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Atea Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sutro Biopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Rocket Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Akebia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Cowin Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule